Validation of a Platelet Proteomic Assay for Diagnosing and Monitoring Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a single center study evaluating whether a new blood test based on platelet proteins rather than plasma proteins can improve detection of prostate cancer and evaluate the degree of serious disease. Currently, doctors rely on multiple tests such as PSA, MRI scans and biopsies to do the same evaluation. Researchers are trying to see if HeLP™ can be a safe and accurate alternative. The study is inviting men who are being seen for suspicion of prostate cancer (based on symptoms or previous lab results). If they agree to be in the study, the research team will take a sample of their blood at the time they are getting a repeat PSA test or having Imaging. The research test does not affect the care they are already receiving and takes 3 extra tubes of blood (\~3 tbsp). The research team is aiming to include 300 participants total. They believe 278 people are needed to confidently compare results between people with and without prostate cancer. They will do an interim analysis halfway through the study, once samples from 150 subjects have been collected. The research is considered low risk-no more uncomfortable or dangerous than a blood draw. There is a risk of loss of privacy, but researchers are taking strong steps to protect privileged information. That includes proper data handling, secure, storage, and making sure the study team is trained in research ethics.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 40 lat
- •Podejrzenie raka prostaty na podstawie objawów lub wyników badań
✗ Disqualifies
- •Poprzednie leczenie raka prostaty
- •Wcześniejsza diagnoza raka prostaty
- •Poważne zaburzenia krzepnięcia krwi
- •Przyjmowanie leków na rozcieńczanie krwi lub aspiryny, ibuprofen, naproksynu lub podobnych leków w ciągu 7 dni przed pobraniem krwi
Simplified criteria — AI translation
Trial details
- Minimum age
- 40 Years
- Last updated (source)
- August 6, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
Duke University
Durham, United States
Trial contact
Judd Moul, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.